This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Nachman Brautbar, MD; Raphael Luboshitzky, MD

Arch Intern Med. 1977;137(7):914-916.

Abstract
Hypercalcemia of multiple myeloma has been discussed widely in the medical literature. The role of calcitonin and phosphate in the treatment of hypercalcemia of multiple myeloma has not yet been studied to our knowledge, although experimental animal models have been pointing to the role of phosphate supplement to calcitonin treatment in multiple myeloma. A patient had multiple myeloma and hypercalcemia. The usual medical treatment for hypercalcemia failed; however, the treatment with combined orally administered phosphate and calcitonin was successful. The role of phosphate depletion in this setting is brought up as an important factor in the failure of calcitonin therapy.

(Arch Intern Med 137:914-916, 1977)

Author Affiliations
From the Nephrology Section (Dr Broutbar), Veterans Administration Wadsworth Hospital Center, the Department of Nephrology (Dr Brautbar), University of California at Los Angeles, and Medical Department (Dr Luboshitzky), Rotchild Hospital, Haifa, Israel. Dr Luboshitzky is now with the Department of Endocrinology, Rambam Hospital, Haifa, Israel.

Footnotes
Accepted for publication Sept 9, 1976.

Reprint requests to Nephrology Section 691/ 151, Veterans Administration Wadsworth Hospital Center, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073 (Dr Brautbar).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?